Form 4: Provectus Biopharmaceuticals CEO Converts Promissory Note to Preferred Stock, Details Equity Holdings

Edward Pershing, CEO and Director of Provectus Biopharmaceuticals, Inc., converted an 8% unsecured convertible promissory note into Series D-1 Convertible Preferred Stock, further detailing his beneficial ownership and future equity structure.

Summary

• Edward Pershing, CEO and Director of Provectus Biopharmaceuticals, Inc. (PVCT), reported a transaction involving the conversion of an 8% unsecured convertible promissory note (the "2022 Note").
• On June 26, 2025, the 2022 Note, with an outstanding principal and interest of $325,000, was automatically converted into 122,692 shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per share.
• Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").
• The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted in accordance with its terms.
• Following this reported transaction, Mr. Pershing beneficially owns 1,585,000 shares of Series D-1 Convertible Preferred Stock and 2,233,424 shares of Common Stock.
• The 2022 Note was originally issued pursuant to the Issuer's 2022 Financing.

Sentiment

Score: 6

Explanation: The filing is a routine disclosure of a pre-planned equity conversion by an insider. While it reduces debt, the future dilution from preferred stock conversion is a consideration. The CEO's continued significant ownership is generally positive for alignment of interests.

Positives

• The conversion of the 8% unsecured convertible promissory note into preferred stock reduces the company's outstanding debt obligations, strengthening its balance sheet.
• The CEO's continued significant beneficial ownership of both preferred and common stock aligns his interests with those of other shareholders.

Negatives

• The future automatic conversion of Series D-1 Convertible Preferred Stock into Common Stock could lead to dilution for existing common shareholders.

Risks

• Potential future dilution of common stock due to the automatic conversion of Series D-1 Convertible Preferred Stock on June 20, 2026, or earlier.

Future Outlook

The Series D-1 Convertible Preferred Stock held by the reporting person is scheduled for automatic conversion into Common Stock on June 20, 2026, unless converted earlier in accordance with its terms.

Industry Context

This Form 4 filing is a routine disclosure of an insider's equity conversion, specific to Provectus Biopharmaceuticals, Inc. While it does not directly reflect broader industry trends, the conversion of debt to equity can be a strategic move for companies in the biotechnology or pharmaceutical sector to manage their balance sheets, particularly those in development stages seeking to reduce cash burn from interest payments.

Related Party Transactions

• The conversion of the 8% unsecured convertible promissory note held by Edward Pershing, the CEO and Director, into Series D-1 Convertible Preferred Stock constitutes a dealing with a related party.

Stakeholder Impact

• Shareholders: The conversion of debt into preferred stock reduces the company's debt burden. However, the future conversion of preferred stock into common stock could lead to dilution for existing common shareholders.
• Creditors: The conversion of the promissory note reduces the company's outstanding debt obligations to the noteholder.

Next Steps

• Automatic conversion of Series D-1 Convertible Preferred Stock into Common Stock on June 20, 2026, unless earlier converted.

Key Dates

Recommendation

Keywords

Provectus Biopharmaceuticals, PVCT, SEC Form 4, Insider Transaction, Beneficial Ownership, Convertible Note, Preferred Stock, Common Stock, Edward Pershing, CEO, Director, Equity Conversion, Debt Conversion